Table 7.
Changes (%) in Hematocrit and Prostate-specific Antigen (PSA) Levels with Testosterone Therapy According to the rs1062033 and rs700518 polymorphisms of the CYP19A1
| Rs1062033 | CC | CG | GG | P value |
|---|---|---|---|---|
| Hematocrit | ||||
| 6 months | 10.29 ± 1.37 | 10.23 ± 1.30 | 11.30 ± 1.97 | 0.89 |
| 12 months | 9.33 ± 1.52 | 9.72 ± 1.44 | 7.77 ± 2.30 | 0.77 |
| 18 months | 9.13 ± 1.56 | 9.67 ± 1.45 | 11.56 ± 2.27 | 0.67 |
| PSA | ||||
| 6 months | 54.78 ± 17.55 | 66.42 ± 15.88 | 68.43 ± 24.73 | 0.86 |
| 12 months | 32.77 ± 10.96 | 43.70 ± 9.92 | 22.64 ± 14.99 | 0.48 |
| 18 months | 56.89 ± 17.30 | 60.70 ± 15.65 | 85.07 ± 23.64 | 0.61 |
| Rs700518 | AA | AG | GG | P value |
| Hematocrit | ||||
| 6 months | 10.81 ± 1.54 | 10.58 ± 1.19 | 10.80 ± 1.90 | 0.99 |
| 12 months | 9.27 ± 1.69 | 10.04 ± 1.33 | 7.64 ± 2.22 | 0.65 |
| 18 months | 9.41 ± 1.73 | 9.71 ± 1.35 | 11.32 ± 2.21 | 0.77 |
| PSA | ||||
| 6 months | 47.65 ± 19.25 | 64.79 ± 14.47 | 77.20 ± 24.55 | 0.62 |
| 12 months | 21.93 ± 12.01 | 44.43 ± 9.03 | 31.53 ± 14.85 | 0.32 |
| 18 months | 45.11 ± 18.71 | 58.55 ± 14.06 | 104.68 ± 23.14 | 0.12 |
Mean± SD